Clinical Evaluation Report (CER) Guide for EU MDR: Requirements, Process & Best Practices

Introduction

The implementation of the European Union Medical Device Regulation (EU MDR) 2017/745 has significantly increased the expectations for demonstrating the safety, clinical performance, and clinical benefits of medical devices. At the center of these requirements is the Clinical Evaluation Report (CER) – a living document that systematically assesses clinical evidence to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs).

Whether you are a medical device manufacturer preparing for CE marking or maintaining compliance throughout your product’s lifecycle, developing a robust CER is essential.

Clinical evaluation has become a continuous process supported by systematic literature reviews, post-market surveillance (PMS), post-market clinical follow-up (PMCF), risk management, and ongoing assessment of the state of the art. As regulatory expectations continue to evolve, manufacturers need CERs that are scientifically robust, traceable, and capable of withstanding Notified Body scrutiny.

What Is a Clinical Evaluation Report?

A CER is a scientific and regulatory document that critically evaluates all available clinical data relating to a medical device. It documents the process of collecting, appraising, and analyzing clinical data to demonstrate that a medical device is safe, performs as intended, and maintains a favorable benefit-risk profile. The objective is to demonstrate that the device:

• Achieves its intended clinical purpose
• Performs as intended under normal conditions of use
• Maintains an acceptable benefit-risk profile
• Meets the applicable General Safety and Performance Requirements (GSPRs) of EU MDR Annex I

Unlike the former Medical Device Directive (MDD), the EU MDR places greater emphasis on continuous clinical evidence generation throughout the device lifecycle. Consequently, the CER is no longer a one-time submission, but a living document that must be updated as new evidence becomes available.

Why CERs Have Become More Challenging Under EU MDR

The introduction of EU MDR has significantly increased the level of clinical evidence expected from manufacturers. Notified Bodies now evaluate CERs with greater emphasis on scientific rigor, transparency, and consistency across the technical documentation.

Several factors have contributed to this increased complexity:

• Higher expectations for clinical evidence
• More stringent requirements for demonstrating equivalence
• Greater reliance on PMS and PMCF data throughout the device lifecycle
• Increased scrutiny of benefit-risk assessments and clinical claims
• More rigorous literature review expectations
• Increased integration between technical documents
• Continuous life cycle management
• Increased documentation and traceability

As portfolios grow, maintaining multiple CERs manually becomes increasingly resource-intensive, particularly for organizations with limited regulatory resources.

Key Components of a High-Quality CER

An effective Clinical Evaluation Report should include:

• A clearly defined Clinical Evaluation Plan (CEP)
• Comprehensive systematic literature review
• Critical appraisal of published clinical evidence
• Analysis of clinical investigations and post-market data
• State-of-the-art evaluation
• Benefit-risk assessment
• Conclusions supported by objective clinical evidence
• Alignment with risk management, PMS, PMCF, and the Technical Documentation.

Perhaps more importantly, every section should demonstrate consistency and traceability. Clinical conclusions should align with device claims, labeling, Instructions for Use (IFU), risk files, and supporting regulatory documentation.

Common Challenges Manufacturers Face

Many organizations find that creating the first CER is only part of the challenge. Maintaining compliance across multiple product families over several years often becomes the greater operational burden.

Common challenges include:

• Managing increasing volumes of published clinical evidence
• Maintaining consistency across multiple CER updates
• Responding efficiently to Notified Body observations
• Preserving traceability between evidence and conclusions
• Coordinating inputs from Regulatory Affairs, Clinical Affairs, Quality, and Medical Writing teams
• Controlling costs while meeting increasingly compressed timelines

Without structured processes, valuable knowledge is often lost as teams change; documents evolve, or external vendors rotate.

From Document Delivery to Regulatory Outcomes

The regulatory landscape has shifted. Manufacturers increasingly require partners who understand the complete regulatory journey rather than simply producing documents.

A successful CER is measured not by the number of pages it contains, but by whether it supports a smooth Notified Body review, reduces regulatory risk, and remains easier to maintain throughout the product lifecycle.

This reflects a broader industry shift from engaging medical writing vendors to working with regulatory partners who combine scientific expertise, regulatory knowledge, and technology-enabled processes.

Building a Sustainable CER Strategy

Long-term success requires more than producing compliant documentation. Organizations should establish repeatable processes that improve quality, preserve institutional knowledge, and simplify future maintenance activities.

Technology is playing an increasingly important role in achieving these objectives. When combined with experienced regulatory professionals, AI can help accelerate literature analysis, evidence organization, consistent reviews, and document updates while maintaining the human oversight required for regulatory decision-making.

The future of CER development lies not in replacing human expertise, but in empowering experts to focus on high-value scientific analysis, critical appraisal, and strategic regulatory decision-making.

Conclusion

Clinical Evaluation Reports remain one of the most important documentations required for EU MDR compliance. As regulatory expectations continue to evolve, manufacturers need more than well-written documents. They need robust clinical strategies, defensible evidence, complete traceability, and processes that support ongoing compliance throughout the product lifecycle.

The organizations best positioned for long-term success are those that combine deep regulatory expertise with technology that improves efficiency without compromising scientific rigor. By building audit-ready CERs supported by structured knowledge and continuous evidence management, manufacturers can reduce rework, improve consistency, and approach every Notified Body review with greater confidence.

Anyone can write the document. We deliver the outcome.

Manufacturers are under increasing pressure to maintain CERs across growing product portfolios while meeting tighter review timelines and evolving regulatory expectations. Success depends on combining deep regulatory expertise with technology that improves efficiency without compromising scientific rigor.

At Celegence, we combine regulatory expertise, accelerated by AI through CAPTIS®, enabling regulatory and clinical teams to develop audit-ready CERs with complete traceability, human expertise, and structured knowledge that makes every maintenance cycle easier than the last.

Whether you’re preparing your first CER, responding to Notified Body observations, or managing an entire portfolio, partnering with the right regulatory team can reduce rework, improve consistency, and help you achieve predictable regulatory outcomes not just deliver another document.

Need support with your Clinical Evaluation Reports?

Whether you’re preparing your first CER, responding to Notified Body observations, or maintaining CERs across an entire product portfolio, Celegence combines regulatory expertise, accelerated by AI through CAPTIS®, to deliver audit-ready documentation, complete traceability, and predictable regulatory outcomes.

Talk to Our CER Experts